GlaxoSmithKline plc Earnings Recaps
Q3 2025
Oct 29, 2025
GSK's Q3 2025 results reflect robust growth with total sales increasing by 8%, driven by strong performance in specialty medicines, and a significant upgrade in guidance for the year. The company also reported positive cash generation and progress in R&D, highlighting its commitment to innovation and sustainability.
Key takeaways
- Total sales reached GBP 8.5 billion in Q3, up 8% year-over-year, with specialty medicines growing 16%.
- Core operating profit increased by 11%, and core EPS rose 14% to 55p.
- GSK secured four FDA approvals this year, including for BLENREP, and expects to launch a low-carbon version of Ventolin in 2026.
- Cash generation stood at GBP 6.3 billion year-to-date, supporting ongoing investments and a quarterly dividend of 16p.
- Full-year specialty guidance has been upgraded from low teens to mid-teens percentage growth.
Q2 2025
Aug 1, 2025
GSK reported robust Q2 2025 results, with group sales increasing by 6%, core operating profit up 12%, and core earnings per share rising 15%, largely driven by strong performance in Specialty Medicines and vaccines.
Key takeaways
- Specialty Medicines sales surged 15%, contributing significantly to overall revenue growth.
- Three FDA approvals achieved year-to-date support GSK’s R&D momentum and pipeline expansion.
- Cash generation was strong, with GBP 3.7 billion generated in the first half, enabling continued investments and shareholder return strategies.
- The company is reaffirming guidance for 2025, now projected toward the higher end of expectations due to strong operational performance.
- A significant share buyback program is underway, with over GBP 800 million completed since February.